Cytokinetics Incorporated's Revenue in the fiscal year 2025 $ 88.04 millions
Cytokinetics Incorporated's Revenue in the fiscal year 2024 $ 18.47 millions
Cytokinetics Incorporated's Revenue in the fiscal year 2023 $ 7.53 millions
Cytokinetics Incorporated's Revenue in the fiscal year 2022 $ 94.59 millions
Cytokinetics Incorporated's Revenue in the fiscal year 2021 $ 70.43 millions
CYTK Revenue third quarter 2026 Y/Y Growth Comment
Cytokinetics Incorporated achieved in the third quarter 2026, above Company average Revenue surge of 2351.39% year on year, to $ 47.56 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Revenue growth. While Cytokinetics Incorporated' s Revenue doubling of 2351.39% ranks overall at the positon no. 56 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Cytokinetics Incorporated's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
7649.83 %
331.09 %
-97.94 %
(Jun 30 2022)
CYTK's III. Quarter Q/Q Revenue Comment
Cytokinetics Incorporated achieved in the III. Quarter 2026 below company average Revenue jump of 66.17% quarter on quarter, to $ 47.56 millions.
III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -97.09% in the III. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Cytokinetics Incorporated's Revenue growth quarter on quarter, overall rank is 251.
Cytokinetics Incorporated achieved in the III. Quarter 2026 below company average Revenue jump of 66.17% quarter on quarter, to $ 47.56 millions.
III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -97.09% in the III. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Cytokinetics Incorporated's Revenue growth quarter on quarter, overall rank is 251.
Cytokinetics Incorporated's 12 Months Revenue Growth Year on Year
For the 12 months ended Jun 30 2026 Cytokinetics Incorporated reported a fall in Revenue by -21.07% year on year, to $68 millions, compare to the 450.6% growth at Mar 31 2026.
Among companies within the Healthcare sector 6 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 17.
For the 12 months ended Jun 30 2026 Cytokinetics Incorporated reported a fall in Revenue by -21.07% year on year, to $68 millions, compare to the 450.6% growth at Mar 31 2026.
Among companies within the Healthcare sector 6 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 7 to 17.
About Cytokinetics Incorporated Revenue Growth Rates (CYTK), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2,356.46%